Literature DB >> 19155082

The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice.

Einar Björnsson1, Loa Davidsdottir.   

Abstract

BACKGROUND/AIMS: Chronic evolution after drug-induced liver injury (DILI) has been reported. How often this leads to liver-related morbidity and mortality is unexplored.
METHODS: Patients who survived DILI and concomitant jaundice reported to the Swedish Adverse Drug Reaction Advisory Committee (1970-2004) were linked to the Swedish Hospital Discharge and Cause of Death Registries.
RESULTS: Among the 712 survivors, 27 could not be retrieved but 685 patients could be linked to the registries, 392 females (57.2%) and 293 males (42.8%) median age 58 (41-74), a mean follow-up of 10 years. A total of 23/685 (3.4%) patients had been hospitalized for liver disease and 5 had liver-related mortality. Eight patients developed cirrhosis (7 decompensated, 5 died), 5 had "cryptogenic" cirrhosis in which DILI might have played a role in this development. Duration of therapy before DILI was longer in patients with liver-related morbidity/mortality (135+/-31 days vs. 53+/-3; p<0.0001). Autoimmune hepatitis developed in 5/23 (22%), all of female gender after a mean of 5.8 years.
CONCLUSIONS: Development of clinically important liver disease after severe DILI associated with jaundice is rare after acute DILI. However decompensated "cryptogenic" cirrhosis developed in some patients with fatal outcome in which DILI might have played a role in this development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19155082     DOI: 10.1016/j.jhep.2008.10.021

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  30 in total

1.  Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.

Authors:  Robert J Fontana; Paul H Hayashi; Jiezhun Gu; K Rajender Reddy; Huiman Barnhart; Paul B Watkins; Jose Serrano; William M Lee; Naga Chalasani; Andrew Stolz; Timothy Davern; Jayant A Talwakar
Journal:  Gastroenterology       Date:  2014-03-27       Impact factor: 22.682

Review 2.  Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.

Authors:  Sarah Tischer; Robert J Fontana
Journal:  J Hepatol       Date:  2013-11-23       Impact factor: 25.083

3.  Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies.

Authors:  Aileen Smith; John Dillon
Journal:  BMJ Case Rep       Date:  2009-09-02

4.  Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Authors:  Harshad Devarbhavi; Guruprasad Aithal; Sombat Treeprasertsuk; Hajime Takikawa; Yimin Mao; Saggere M Shasthry; Saeed Hamid; Soek Siam Tan; Cyriac Abby Philips; Jacob George; Wasim Jafri; Shiv K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

Review 5.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 6.  An Update on Drug-induced Liver Injury.

Authors:  Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

7.  Predicting fatalities in serious idiosyncratic drug-induced liver injury-a matter of choosing the best Hy's law.

Authors:  Fernando Bessone
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-18

8.  Mortality associated with drug-induced liver injury (DILI).

Authors:  Einar S Björnsson; Helgi K Björnsson
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-19

Review 9.  Risk factors for idiosyncratic drug-induced liver injury.

Authors:  Naga Chalasani; Einar Björnsson
Journal:  Gastroenterology       Date:  2010-04-12       Impact factor: 22.682

Review 10.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

Authors:  Robert J Fontana
Journal:  Gastroenterology       Date:  2013-12-31       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.